How do cancers become resistant to chemotherapy?

April 3, 2012

Genetic mutations in cancer cells can lead to resistance to treatment, thereby potentially resulting in relapse. However, a new article, published April 3 in the magazine section of the online, open-access journal PLoS Biology, suggests that the converse may also happen. Steven Frank from the University of California, Irvine, and Marsha Rosner from the University of Chicago, propose that it may often be the case that a few cells become resistant before any genetic change, and then later acquire the genes to stabilize that resistance.

Why does it matter whether resistance comes before , or vice versa? Because the effectiveness of treatment depends primarily on preventing resistance. If, as is the current view, genetic mutations occur first and then spread to cause resistance, then treatment protocols must focus on preventing the origination of with the particular set of mutations that cause this resistance. Widely used combination therapies are designed specifically to limit the chance that a cancer cell can develop the suite of mutations necessary for resistance.

Frank and Rosner argue that a few cells may often become resistant before they get specific genetic mutations. Such non-genetic resistance may occur through the random variation in cellular characteristics that has been widely observed among genetically identical cells. Alternatively, non-genetic resistance may occur when cells change (essentially reprogram) their characteristics in response to the stress of moving into new tissues, or dealing with . Cells are known to have many flexible programs of expression in response to a change in their environment. If cells first become resistant by either non-genetic randomness or flexibility, then those can later acquire genetic changes to stabilize their resistance. Such a progression that starts with non-genetic resistance necessarily alters one's ideas as to how to design combinations of drugs aimed at preventing relapse.

The idea that non-genetic resistance comes first is not entirely new. But the small amount of existing evidence has not led to a change in how people view the issue. This new article aims to bring this perspective to a wider group of researchers by combining the evidence from prior studies with a clear understanding of the evolutionary theory by which populations adapt to extreme challenges. New studies, designed in the light of how evolution might occur in cancers, will show whether alternative approaches to treatment can improve outcomes.

Explore further: Researchers develop new technology to screen and analyze genetic mutations

More information: Frank SA, Rosner MR (2012) Nonheritable Cellular Variability Accelerates the Evolutionary Processes of Cancer. PLoS Biol 10(4): e1001296. doi:10.1371/journal.pbio.1001296

Related Stories

Researchers develop new technology to screen and analyze genetic mutations

April 7, 2011
A single change to even one of the thousands of DNA codes that make up each gene in the human genome can result in severe diseases such as cancer, cystic fibrosis, muscular dystrophy or Huntington's Disease. A similarly minor ...

Research provides insight into new drug resistance in hospital microbes

July 13, 2011
Hospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to ...

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

nanotech_republika_pl
not rated yet Apr 04, 2012
"Such non-genetic resistance may occur through the random variation in cellular characteristics that has been widely observed among genetically identical cells."

Huh? Like what variation in cellular characterists? Thru epigenetics, right?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.